These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 9141462)
1. Studies of neoplasia in the Min mouse. Shoemaker AR; Gould KA; Luongo C; Moser AR; Dove WF Biochim Biophys Acta; 1997 Apr; 1332(2):F25-48. PubMed ID: 9141462 [No Abstract] [Full Text] [Related]
2. E-cadherin and adenomatous polyposis coli mutations are synergistic in intestinal tumor initiation in mice. Smits R; Ruiz P; Diaz-Cano S; Luz A; Jagmohan-Changur S; Breukel C; Birchmeier C; Birchmeier W; Fodde R Gastroenterology; 2000 Oct; 119(4):1045-53. PubMed ID: 11040191 [TBL] [Abstract][Full Text] [Related]
3. Action of Min and Mom1 on neoplasia in ectopic intestinal grafts. Gould KA; Dove WF Cell Growth Differ; 1996 Oct; 7(10):1361-8. PubMed ID: 8891340 [TBL] [Abstract][Full Text] [Related]
5. The tumour suppressor APC gene product is associated with cell adhesion. Burchill SA Bioessays; 1994 Apr; 16(4):225-7. PubMed ID: 8031298 [No Abstract] [Full Text] [Related]
6. Intestinal tumor load in the Min/+ mouse model is not correlated with eicosanoid biosynthesis. Whelan J; Chiu CH; McEntee MF Adv Exp Med Biol; 1999; 469():607-15. PubMed ID: 10667389 [No Abstract] [Full Text] [Related]
7. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis. Li Q; Ishikawa TO; Oshima M; Taketo MM Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028 [TBL] [Abstract][Full Text] [Related]
8. Tumor-associated Apc mutations in Mlh1-/- Apc1638N mice reveal a mutational signature of Mlh1 deficiency. Kuraguchi M; Edelmann W; Yang K; Lipkin M; Kucherlapati R; Brown AM Oncogene; 2000 Nov; 19(50):5755-63. PubMed ID: 11126362 [TBL] [Abstract][Full Text] [Related]
9. Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Orner GA; Dashwood WM; Blum CA; Díaz GD; Li Q; Al-Fageeh M; Tebbutt N; Heath JK; Ernst M; Dashwood RH Mutat Res; 2002 Sep; 506-507():121-7. PubMed ID: 12351151 [TBL] [Abstract][Full Text] [Related]
10. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice. Sansom OJ; Stark LA; Dunlop MG; Clarke AR Cancer Res; 2001 Oct; 61(19):7060-4. PubMed ID: 11585736 [TBL] [Abstract][Full Text] [Related]
11. [Use of Apc(Min/+) mouse model in the studies of intestinal tumors]. Sheng HQ; Chen J; Lai MD Yi Chuan; 2008 Mar; 30(3):277-82. PubMed ID: 18331993 [TBL] [Abstract][Full Text] [Related]
13. Oncogenic targets of beta-catenin-mediated transcription in molecular pathogenesis of intestinal polyposis. Watson SA Lancet; 2001 Feb; 357(9256):572-3. PubMed ID: 11558478 [No Abstract] [Full Text] [Related]
14. Adenomatous polyposis coli gene as a gatekeeper. Nakayama T; Morishita T; Kamiya T Rev Gastroenterol Peru; 2002; 22(2):164-7. PubMed ID: 12098745 [TBL] [Abstract][Full Text] [Related]
15. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Wechter WJ; Kantoci D; Murray ED; Quiggle DD; Leipold DD; Gibson KM; McCracken JD Cancer Res; 1997 Oct; 57(19):4316-24. PubMed ID: 9331093 [TBL] [Abstract][Full Text] [Related]
16. APC and intestinal carcinogenesis. Insights from animal models. Bertagnolli MM Ann N Y Acad Sci; 1999; 889():32-44. PubMed ID: 10668480 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. Churchill M; Chadburn A; Bilinski RT; Bertagnolli MM J Surg Res; 2000 Apr; 89(2):169-75. PubMed ID: 10729246 [TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Koehl GE; Spitzner M; Ousingsawat J; Schreiber R; Geissler EK; Kunzelmann K Oncogene; 2010 Mar; 29(10):1553-60. PubMed ID: 19966863 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490 [TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. Roy HK; Karoski WJ; Ratashak A; Smyrk TC Br J Cancer; 2001 May; 84(10):1412-6. PubMed ID: 11355956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]